Pemetrexed, Cisplatin With Soft Tissue Sarcoma

Launched by YONSEI UNIVERSITY · Oct 26, 2020

Keywords

ClinConnect Summary

This clinical trial is studying a combination of two chemotherapy drugs, pemetrexed and cisplatin, to see how well they work in treating advanced or metastatic soft tissue sarcoma (STS). Soft tissue sarcoma is a rare type of cancer that can be challenging to treat, especially after patients have already tried other treatments. The goal of this trial is to find out if this combination therapy can help patients whose cancer has not responded to previous therapies. Researchers are particularly interested in seeing how effective this treatment is for different subtypes of STS.

To be eligible for this trial, participants must be at least 19 years old and have a confirmed diagnosis of advanced STS that can be measured, meaning doctors can track if the cancer is getting better or worse. They should also have a good performance status, which means they are generally able to carry out daily activities. Patients who have already received two or more chemotherapy treatments or have certain health issues may not be able to participate. Those who join can expect to receive the study treatment and will be closely monitored for any side effects or changes in their condition. This trial is currently recruiting, and it aims to gather important information that could lead to better treatment options for patients with soft tissue sarcoma.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • histologically confirmed, advanced/metastatic STS
• • Is ≥ 19 years of age
• • Eastern Cooperative Oncology Group performance status of 0 or 1
• • measurable disease per Response Evaluation Criteria in Solid Tumors Version 1.1
• • laboratory values indicating adequate organ function
• • a documented postmenopausal woman, or is a premenopausal woman with negative urine or serum pregnancy test
• • life expectancy ≥ 12 weeks
• Exclusion Criteria:
• • previously received more than 2 regimens of cytotoxic chemotherapy
• • received chemotherapy, surgery to major organ, or radiotherapy within the last 2 weeks
• • ongoing toxicity (≥ CTCAE grade 2) from previous anticancer therapy
• • central nervous system (CNS) metastases requiring active treatment
• • diagnosis of second malignancy or has a history of active malignancy within the past 3 years
• • other medical conditions where the study treatment is intolerable
• • history of active infection
• • hypersensitivity to pemetrexed or any of its excipients
• • Co-administration with yellow fever vaccine
• • pregnancy